Oculis

The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.

Oculis headquartered in Europe, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $44.4B in funding across 156 round(s). With a team of 11-50 employees, Oculis is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Oculis, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.